Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 03/28/24
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesPRNewsWire • 01/08/24
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 11/09/23
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigrainePRNewsWire • 09/19/23
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 09/11/23
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazolePRNewsWire • 08/23/23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 08/10/23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigrainePRNewsWire • 07/11/23
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache SocietyPRNewsWire • 06/15/23
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International ConventionPRNewsWire • 05/24/23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 05/12/23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate UpdatePRNewsWire • 03/30/23
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with AsthmaPRNewsWire • 02/06/23
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"PRNewsWire • 01/25/23
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and ImmunologyPRNewsWire • 01/23/23
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute MigrainePRNewsWire • 01/04/23
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 11/10/22
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute MigrainePRNewsWire • 09/26/22
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/08/22
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute MigrainePRNewsWire • 07/12/22
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/12/22
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate UpdatePRNewsWire • 03/29/22
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic ResultsBenzinga • 03/21/22
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPDPRNewsWire • 03/21/22